DAPAGLIFLOZIN
DAPAGLIFLOZIN is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: DAPAGLIFLOZIN; Generic name: DAPAGLIFLOZIN; Drug class: Sodium-Glucose Cotransporter 2 Inhibitor [EPC].
| Brand name | DAPAGLIFLOZIN |
|---|---|
| Generic name | DAPAGLIFLOZIN |
| Drug class | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] |
| Manufacturer | Teva Pharmaceuticals, Inc. |
| Used for | 1 INDICATIONS AND USAGE Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions ( 5.1 )]. Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . Dapaglifl |
| Dosage | 2 DOSAGE AND ADMINISTRATION Assess renal function prior to initiation and then as clinically indicated. Assess volume status and correct volume depletion before initiating. ( 2.1 ) To improve glycemic control, the recommended starting dosage is 5 mg orally once daily. Dosage can be increased to 10 mg orally once daily for additional glycemic control. ( 2.2 ) To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disea |
| Active ingredient(s) | DAPAGLIFLOZIN |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0406a1c0-56b1-4ea1-95ae-00357ac1ba7e |